MTOR and hepatocellular carcinoma: To investigate whether PGRN-stimulated mTOR signaling could be a therapeutic target in HCC, we subcutaneously injected nude mice with HepG2 cells administered with or without rhPGRN in the absence or presence of rapamycin.